Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 15.2K citations · Full text

Medicine, Clinical Sciences, Oncology +12

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert, Jacob Schachter, Georgina V. Long et al. · New England Journal of Medicine · 2015 · 5.8K citations · Full text

Life Sciences, Oncology, Pharmacotherapy +17

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation

Caroline Robert, Georgina V. Long, Benjamin Brady et al. · New England Journal of Medicine · 2014 · 5.4K citations · Full text

Medicine, Oncology, Pharmacotherapy +14

A Multiple Testing Procedure for Clinical Trials

Peter C. O’Brien, Thomas R. Fleming · Biometrics · 1979 · 3.3K citations

Public Health, Biostatistics, Evidence-based Practice +13